Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
CONCLUSIONS: Our early-phase data suggested that ipilimumab plus lenalidomide is well tolerated after HSCT. Adverse events did not differ significantly between the allogeneic and autologous groups.
PMID: 29246938 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour E, Milton DR, Bassett RL, Vence L, Allison JP, Gulbis AM, Sharma P Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Dermatitis | Dermatology | Hypothyroidism | Oral Cancer | Revlimid | Stem Cell Therapy | Stem Cells | Toxicology | Transplants | Yervoy